Halozyme Therapeutics (Halozyme Therapeutics) EV-to-EBIT : 16.52 (As of Apr. 28, 2024)

Halozyme Therapeutics EV-to-EBIT Chart

Halozyme Therapeutics Annual Data
	Trend	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21	Dec22	Dec23
EV-to-EBIT		Get a 7-Day Free Trial					-39.67	38.72	22.12	33.23	15.93

Halozyme Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial															33.23	25.34	18.98	18.03	15.93

Competitive Comparison of Halozyme Therapeutics's EV-to-EBIT

For the Biotechnology subindustry, Halozyme Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Halozyme Therapeutics's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Halozyme Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Halozyme Therapeutics's EV-to-EBIT falls into.

Halozyme Therapeutics EV-to-EBIT Calculation

Halozyme Therapeutics's EV-to-EBIT for today is calculated as:

Halozyme Therapeutics's current Enterprise Value is $6,063.7 Mil.
Halozyme Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $367.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics  (NAS:HALO) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Halozyme Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Halozyme Therapeutics's Enterprise Value for the quarter that ended in Dec. 2023 was $5,848.7 Mil.
Halozyme Therapeutics's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $367.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Halozyme Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Halozyme Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Halozyme Therapeutics (Halozyme Therapeutics) Business Description